Vaccines
25 February 2013
Dynavax Receives FDA Complete Response Letter on HEPLISAV(TM) Biologic License Application25 February 2013
Circassia’s ToleroMune Cat Allergy Treatment Maintains Symptom Improvement Two Years After Start of Short-Course Therapy24 February 2013
European Medicines Agency Recommends Approval of Hexyon/Hexacima 6-in-1 Pediatric Vaccine21 February 2013
Data Published in PLOS ONE Show Mymetics’ HIV-1 Innovative Vaccine is Safe and Elicits Strong Immunogenicity14 February 2013
Argos Therapeutics Announces Updated Phase 2 Data for AGS-003 Personalized Immunotherapy for Metastatic Renal Cell Carcinoma12 February 2013
EpiVax-Novozymes Tregitope-Albumin Fusion Moves ‘Paradigm-Shifting’ Treatment for Diabetes Closer to Clinical Trials12 February 2013
Intercell announces pediatric approval of its Japanese Encephalitis vaccine in Europe4 February 2013
Data from Historic Phase IIb Clinical Trial for Tuberculosis Vaccine Candidate MVA85A Published in The Lancet1 February 2013
Major Commitment Achieved for Development of Vaccines Against Pregnancy-Associated Malaria29 January 2013
ImmunoCellular Therapeutics’ Investigational New Drug (IND) Application for ICT-140 Allowed by the FDA29 January 2013
OncoPep Initiates Phase 1/2a Clinical Trial with Multi-Peptide Vaccine to Treat Smoldering Multiple Myeloma23 January 2013
Cytos to regain rights to Smoking Cessation Vaccine22 January 2013
Emergent BioSolutions Initiates Phase 2 Study in Pursuit of a Post-Exposure Prophylaxis Indication for BioThrax22 January 2013
Novartis receives EU approval for Bexsero®, first vaccine to prevent the leading cause of life-threatening meningitis across Europe17 January 2013
Emergent BioSolutions Initiates Phase 2 Clinical Trial for Next Generation Anthrax Vaccine NuThrax10 January 2013
GeoVax Announces Enrollment Completion for Phase 1/2 Clinical Trial for HIV/AIDS Therapeutic Vaccine9 January 2013
Positive Interim Safety Analysis Achieved in Breast Cancer Patients Treated with HER2/neu AntigensNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports